HIS is a rejection of therapies based on monoclonal to cure the coronavirus. Andrea Crisanti, a microbiologist at the University of Padua, is adamant in rejecting this treatment. For anti-Covid treatments, it is necessary to focus “on anti-inflammatories and anticoagulants; monoclonal antibodies have been imposed on Italy by a lobby of interest”, explains the microbiologist, in an interview with Famiglia Cristiana in the issue on newsstands from Thursday. Monoclonal antibodies, Crisanti emphasizes, “have not spread in America because they don’t work”. While in the same article Crisanti promotes the immunizations of AstraZeneca and Johnson & Johnson calling them “extremely safe vaccines“.
We therefore return to talking about monoclonals and Covid. In Italy this therapy was started in mid-April in Liguria, the first Italian region to join this treatment. In some Ligurian centers, Bamlanivimab monoclonal antibodies are used, authorized for emergency use as a treatment for high-risk patients. They are intended for non-hospitalized patients who, however, must meet certain characteristics. As explained by the director of the Infectious Diseases Clinic of San Martino in Genoa, Matteo Bassetti, the protocol provides as a deadline that of 10 days from the onset of symptoms. This is why synergy with family doctors is very important.
The new therapies / Friuli
Covid: “Here we treat it with monoclonal antibodies”
by Giacomina Pellizzari
Monoclonal antibodies
Monoclonals are considered to be among the most effective weapons for curing Covid-19. At the moment the cocktail of the Regeneron and the Eli Lilly’s drug. The first became famous for having also been used by the former president of the United States, Donald Trump. Manufactured by the American pharmaceutical company Regeneron, it is based on casirivimab and imdevimab antibodies. The first was isolated in a Singaporean patient and the second was obtained in the laboratory by inserting the coronavirus spike protein into the organism of a generically modified mouse.
According to the research results, it would be able to significantly reduce the viral load and reduce the risk of contracting the infection by 50 percent. This has opened up the possibility of using this cocktail as a “passive vaccine“, pending greater availability of anti-Covid vaccines. The data indicate that the drug can at the same time reduce the viral load of infected individuals.
The Bamlanivimab is the monoclonal antibody authorized for emergency use as a treatment for high-risk patients in the United States and other countries around the world. Produced by Eli Lilly and Company, the studies show 72 percent effectiveness in reducing the risk of hospitalization for patients with moderate symptoms.
Bamlanivimab and etesevimab is the combination of Eli Lilly antibodies that studies show to be able to reduce the risk of hospitalization and death from Covid-19 by 70 percent. The two monoclonals were tested in high-risk patients recently diagnosed with Covid-19. The results show that they are also able to reduce viral load and accelerate the resolution of symptoms.
Cure for Covid, what we know about drugs
by Valentina Arcovio
.